RayBerganMD

Oncology • Omaha, NE

Genitourinary Oncology

Deputy Director, Fred & Pamela Buffett Cancer Center, Professor Eppley Cancer Institute

Join to view full profile

Dr. Bergan is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Bergan's full profile

Already have an account?

Office
986805 Nebraska Medical Center
Omaha, NE 68198
Phone+1 402-559-9536

Fax+1 402-559-4238
Is this information wrong?

Summary

Dr. Ray Bergan is a medical oncologist and basic cancer scientist in Omaha, NE and is affiliated with the Fred & Pamela Buffett Cancer Center, University of Nebraska Medical Center. He completed fellowships in medical oncology and drug discovery from the National Cancer Institute, Bethesda, MD. He specializes in early phase therapeutics, genitourinary cancer and cancer prevention.

Clinical Expertise

Genitourinary cancer, Preventive medicine, Clinical research, Laboratory research, Medical oncology

Education & Training

University of Nebraska Medical Centercurrently matriculated, Academic Leaders Course, 2021 - 2022
Harvard, T.H. Chan School of Public HealthCertificate of Completion, Leadership Development Course, 2015 - 2015
National Cancer InstituteLab research, cell biology, 1993 - 1998
National Institutes of Health Clinical CenterFellowship, Hematology and Medical Oncology, 1990 - 1993
SUNY Upstate Medical UniversityResidency, Internal Medicine, 1987 - 1990
SUNY Upstate Medical UniversityClass of 1987

Certifications & Licensure

NE State Medical License 2020 - 2024
OR State Medical License 2015 - 2023
IL State Medical License 1998 - 2017
MD State Medical License 1991 - 1998
American Board of Internal Medicine Medical Oncology

Clinical Trials

Iloprost in Preventing Lung Cancer in Former Smokers Start of enrollment: 2015 Nov 05
Completed
Phase 1
The Registry of Oncology Outcomes Associated With Testing and Treatment Start of enrollment: 2021 May 05
Recruiting
Oltipraz in the Prevention of Lung Cancer in People Who Smoke Start of enrollment: 2000 Aug 01
Completed
Phase 1
Genistein in Treating Patients With Localized Prostate Cancer Who Are Planning to Undergo Radical Prostatectomy Start of enrollment: 2002 Dec 01
Terminated
Phase 2
Se-Methyl-Seleno-L-Cysteine or Selenomethionine in Preventing Prostate Cancer in Healthy Participants Start of enrollment: 2011 Nov 01
Completed
Phase 1
Se-Methyl-Seleno-L- Cysteine (MSC) in Treating Healthy Patients Start of enrollment: 2007 Jul 01
Completed
Phase 1
Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial Start of enrollment: 2020 Apr 01
Terminated
Phase 1
Clinical Trial of Green Tea Catechins in Men on Active Surveillance Start of enrollment: 2020 Aug 21
Recruiting
Phase 2
Berberine Chloride in Preventing Colorectal Cancer in Patients With Ulcerative Colitis in Remission Start of enrollment: 2016 Jun 16
Completed
Phase 1
S0820, Adenoma and Second Primary Prevention Trial Start of enrollment: 2013 Aug 23
Active, not recruiting
Phase 3
Transdermal or Oral Telapristone Acetate in Treating Patients Undergoing Mastectomy Start of enrollment: 2015 Oct 01
Completed
Phase 2
Genistein in Treating Patients With Prostate Cancer Start of enrollment: 2011 Feb 03
Terminated
Phase 2
Inositol in Preventing Colorectal Cancer in Patients With Colitis-Associated Dysplasia Start of enrollment: 2010 Oct 01
Terminated
Phase 1, Phase 2
Erlotinib Hydrochloride in Preventing Cancer in Patients With Precancerous Lesions of the Lung Start of enrollment: 2009 Oct 01
Terminated
Phase 1
Macrogol 3350-based Oral Osmotic Laxative in Preventing Cancer in Patients at Risk of Colorectal Cancer Start of enrollment: 2009 Oct 01
Completed
Phase 2
Aspirin in Preventing Colorectal Cancer in Patients at Increased Risk of Colorectal Cancer Start of enrollment: 2007 Mar 01
Completed
Phase 2
4-Hydroxytamoxifen or Tamoxifen Citrate in Treating Women With Newly Diagnosed Ductal Breast Carcinoma in Situ Start of enrollment: 2009 Dec 01
Completed
Phase 2
Photodynamic Therapy Using Aminolevulinic Acid in Treating Patients With Oral Leukoplakia Start of enrollment: 2008 Mar 01
Terminated
Phase 1
Genistein in Preventing Breast Cancer in Women at High Risk for Breast Cancer Start of enrollment: 2006 Jan 01
Completed
Phase 2
Join now to see all

Publications & Presentations

PubMed

Comparison of sequential versus concurrent chemoradiation regimens in non-metastatic muscle-invasive bladder cancer.
Heidi M Vieira, David P Kasper, Runqiu Wang, Lynette M Smith, Charles A Enke, Raymond C Bergan, Benjamin A Teply, Michael J Baine> ;Radiation Oncology Journal. 2023 Sep 1
3 citations
FDA Approval Summary: Belzutifan for VHL Disease Tumors-Letter.
Jonathan Q Trinh, Moataz Ellithi, Nicole Shonka, Raymond C Bergan> ;Clinical Cancer Research. 2023 Feb 1
Phase Ib trial of inhaled iloprost for the prevention of lung cancer with predictive and response biomarker assessment.
York E Miller, Moumita Ghosh, Daniel T Merrick, Brandi Kubala, Eva Szabo, Lisa Bengtson, Masha Kocherginsky, Irene B Helenowski, Kelly Benante, Tia Schering, Jihye Kim...> ;Frontiers in Oncology. 2023 Jan 1
1 citations
Micronuclei in Circulating Tumor Associated Macrophages Predicts Progression in Advanced Colorectal Cancer.
Dimpal M Kasabwala, Raymond C Bergan, Kirby P Gardner, Rena Lapidus, Susan Tsai, Mohammed Aldakkak, Daniel L Adams> ;Biomedicines. 2022 Nov 11
7 citations
An omic and multidimensional spatial atlas from serial biopsies of an evolving metastatic breast cancer.
Brett E Johnson, Allison L Creason, Jayne M Stommel, Jamie M Keck, Swapnil Parmar, Courtney B Betts, Aurora Blucher, Christopher Boniface, Elmar Bucher, Erik Burlingam...> ;Cell Reports. Medicine. 2022 Feb 15
74 citations
A phase II single-arm study of pembrolizumab with enzalutamide in men with metastatic castration-resistant prostate cancer progressing on enzalutamide alone
Julie N Graff, Tomasz M. Beer, Joshi J. Alumkal, Rachel Slottke, William L. Redmond, George Thomas, Reid F Thompson, Mary A. Wood, Yoshinobu Koguchi, Yiyi Chen, Emile ...> ;Journal for Immunotherapy of Cancer. 2020 Jul 1
6 citations
Snapshot: Trial Types in Precision Medicine.
Dane Dickson, Jennifer E. Johnson, Raymond C. Bergan, Rebecca Owens, Vivek Subbiah, Razelle Kurzrock> ;Cell. 2020 Apr 2
35 citations
The Master Observational Trial: A New Class of Master Protocol to Advance Precision Medicine.
Dane Dickson, Jennifer E. Johnson, Raymond C. Bergan, Rebecca Owens, Vivek Subbiah, Razelle Kurzrock> ;Cell. 2020 Jan 9
9 citations
DNA Repair Gene Alterations and PARP Inhibitor Response in Patients With Metastatic Castration-Resistant Prostate Cancer.
Eric Lu, George Thomas, Yiyi Chen, Alexander W. Wyatt, Paul Lloyd, Jack F. Youngren, David A. Quigley, Raymond C. Bergan, Shawna Bailey, Tomasz M. Beer, Felix Y. Feng,...> ;Journal of the National Comprehensive Cancer Network. 2018 Aug 1
16 citations
Selenomethionine and methyl selenocysteine: multiple-dose pharmacokinetics in selenium-replete men.
James Roger Marshall, Raymond F. Burk, Rochelle Payne Ondracek, Kristina E. Hill, Marjorie Perloff, Warren Davis, Roberto Pili, Saby George, Raymond C. Bergan> ;Oncotarget. 2017 Feb 17
278 citations
Early evidence of anti-PD-1 activity in enzalutamide-resistant prostate cancer
Julie N. Graff, Joshi J. Alumkal, Charles G. Drake, George Thomas, William L. Redmond, Mohammad Farhad, Jeremy Cetnar, Frederick S. Ey, Raymond C. Bergan, Rachel Slott...> ;Oncotarget. 2016 Jul 12
34 citations
Genistein suppresses FLT4 and inhibits human colorectal cancer metastasis
Xiao Xiao, Zhiguo Liu, Rui Wang, Jiayin Wang, Song Zhang, Xiqiang Cai, Kaichun Wu, Raymond C. Bergan, Li Xu, Daiming Fan> ;Oncotarget. 2015 Jan 10
56 citations
A Randomized Phase II Presurgical Trial of Transdermal 4-Hydroxytamoxifen Gel versus Oral Tamoxifen in Women with Ductal Carcinoma In Situ of the Breast
Oukseub Lee, Katherine Page, David Ivancic, Irene Helenowski, Vamsi Parini, Megan E. Sullivan, Julie A. Margenthaler, Robert T. Chatterton, Borko Jovanovic, Barbara K....> ;Clinical Cancer Research. 2014 Jul 15
42 citations
Heat shock protein 27 regulates human prostate cancer cell motility and metastatic progression
Eric Voll, Irene M. Ogden, Janet M. Pavese, Xiao Ke Huang, Li Xu, Borko Jovanovic, Raymond C. Bergan> ;Oncotarget. 2014 Apr 21
22 citations
Improving diversity in cancer research trials: the story of the Cancer Disparities Research Network.
Melissa A. Simon, Erika E. de la Riva, Raymond C. Bergan, Carrie Norbeck, June M. McKoy, Piotr Kulesza, XinQi Dong, Julian C. Schink, Linda Fleisher> ;Journal of Cancer Education. 2014 Feb 13
7 citations
Therapeutic modulation of prostate cancer metastasis
Sankar N. Krishna, Raymond C. Bergan> ;Future Medicinal Chemistry. 2014 Jan 28
108 citations
Soy isoflavone supplementation for breast cancer risk reduction: a randomized phase II trial.
Seema A. Khan, Robert T. Chatterton, Nancy Michel, Michelle Bryk, Oukseub Lee, David Ivancic, Richard Heinz, Carola M. Zalles, Irene Helenowski, Borko Jovanovic, Adria...> ;Cancer Prevention Research. 2012 Feb 1
1 citations
The Ninth Annual American Association for Cancer Research International Conference on Frontiers in Cancer Prevention Research
Li Xu, Sophia S. Wang, Megan A. Healey, Jessica M. Faupel-Badger, Jason A. Wilken, Tracy A. Battaglia, Eva Szabo, Jenny T. Mao, Raymond C. Bergan> ;Cancer Prevention Research. 2011 Apr 1
25 citations
Concise Syntheses of the Abyssinones and Discovery of New Inhibitors of Prostate Cancer and MMP-2 Expression
Rebecca L. Farmer, Margaret M. Biddle, Antoinette E. Nibbs, Xiaoke Huang, Raymond C. Bergan, Karl A. Scheidt> ;ACS Medicinal Chemistry Letters. 2010 Nov 11
128 citations
Inhibition of cancer cell invasion and metastasis by genistein
Janet M. Pavese, Rebecca L. Farmer, Raymond C. Bergan> ;Cancer Metastasis Reviews. 2010 Aug 24
62 citations
Labeling TiO2 Nanoparticles with Dyes for Optical Fluorescence Microscopy and Determination of TiO2–DNA Nanoconjugate Stability
Kenneth T. Thurn, Tatjana Paunesku, Aiguo Wu, Eric Brown, Barry Lai, Stefan Vogt, Jörg Maser, Mohammed Aslam, Vinayak P. Dravid, Raymond C. Bergan, Gayle E. Woloschak> ;Small. 2009 Jun 5
123 citations
Dietary genistein inhibits metastasis of human prostate cancer in mice.
Minalini Lakshman, Li Xu, Vijayalakshmi Ananthanarayanan, Joshua Cooper, Chris H. Takimoto, Irene Helenowski, Jill C. Pelling, Raymond C. Bergan> ;Cancer Research. 2008 Mar 15
71 citations
Inhibition of HIF‐1 alpha and VEGF expression by the chemopreventive bioflavonoid apigenin is accompanied by Akt inhibition in human prostate carcinoma PC3‐M cells
Salida Mirzoeva, Nam Deuk Kim, Karen Chiu, Carrie A. Franzen, Raymond C. Bergan, Jill C. Pelling> ;Molecular Carcinogenesis. 2008 Sep 1
Associations of serum carotenoid levels with serum insulin-like growth factor-i and insulin-like growth factor binding protein-3 levels in black men and white men.
Young L. Kim, David R. Jacobs, Myron D. Gross, Raymond C. Bergan, Peter H. Gann, Kiang Liu, Susan M. Gapstur> ;Cancer Epidemiology, Biomarkers & Prevention. 2007 Dec 1
57 citations
RENAL MEDULLARY CARCINOMA AND ABL GENE AMPLIFICATION
Lijo Simpson, Xiang He, Michael R. Pins, Xiaoke Huang, Steven C. Campbell, Ximing J. Yang, Elizabeth J. Perlman, Raymond C. Bergan> ;The Journal of Urology. 2005 Jun 1
Join now to see all

Authored Content

Assessing the State of Cancer Research: Insights from an Innovative Clinician-ScientistFebruary 2022
Assessing the State of Cancer Research: Insights from an Innovative Clinician-ScientistFebruary 2022

Press Mentions

Assessing the State of Cancer Research: Insights from an Innovative Clinician-ScientistJuly 10th, 2022
Why Your Doctor Should Also Be a ScientistJuly 10th, 2022

Grant Support

Fred & Pamela Buffett Cancer CenterNational Cancer Institute2021–2026
Inhibiting Bone Destruction by Prostate Cancer with Dual-Acting Bone-Defending AgentsDOD, Prostate Cancer Research Program, Idea Development Award2020–2023
Knight Cancer InstituteNational Cancer Institute2017–2022
The Quantitation of Protein Interactions in Cancer CellsNIH2016–2021
Serial Measurement of Molecular Architecture and Response to TherapyProspect Creek Foundation2016–2019
Inhibiting prostate cancer cell motilityDepartment of Defense, Prostate Cancer Research Program, Laboratory-Clinical Transition Award2015–2019
Therapeutically targeting cancer cell motilityVeterans Administration Merit Award2015–2019
NCI Community Oncology Research ProgramNIH/NCI2015–2019
Phase I study of berberine in inflammatory bowel disease (China-based clinical trial)NIH/NCI2015–2018
Discovery of Selective MAP2K4 Inhibitors to Target MetastasisNIH/NCI2015–2018
Rapid identification of tumor cells, immune reactivity and drug response via microfiltration of cancer patient bloodDefense Advanced Research Projects Agency2015–2017
Cancer Prevention Agent Development Program: Early Phase Clinical ResearchNIH/NCI2012–2015
Robert H. Lurie Cancer CancerNIH/NCI2001–2015
Genistein-mediated regulation of prostate cancer cell motilityNIH/NCI2008–2014
Prostate SPORENIH/NCI2003–2014
Biomarker Identification Core, Prevention CenterNIH/NCI2003–2014
Center of Excellence for Chemoprevention Drug Development: Phase 1 and Phase 2 Clinical Trials of Cancer Chemopreventive AgentsNIH/NCI2003–2014
TiO2 Nanocomposites for Targeted Treatment and Imaging of Prostate Cancer, Nanomaterials for Cancer Diagnostics and Therapeutics CenterNIH/NCI2006–2010
Regulation and Modulation of Prostate Cell MetastasisVA Merit Review Award2004–2009
Molecular Correlates of Soy in HumansNIH/NCI2002–2005
Clinical Phase I Multiple Dose Safety Study of the Combination of NAC and Oltipraz in SmokersNIH/NCI1999–2004